IC
COGT icon

Ikarian Capital’s Cogent Biosciences COGT Stock Holding History

Ikarian Capital’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-262,600
Closed -$1.89M – 177
2025
Q2 		$1.89M Buy
+262,600
New +$1.46M 0.36% 69

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ikarian Capital's COGT Position: Q2 2026 in Review

Ikarian Capital opened a new position in Cogent Biosciences (COGT) in Q2 2026: 370,084 shares worth $14.3M. The stake represents 1.54% of the portfolio and ranks #17 among its holdings. This is a return to the name: Ikarian Capital previously reported a position in COGT as recently as Q3 2025.

Ikarian Capital first reported a position in COGT in Q4 2020 and has held it in 13 quarters since. 324 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • Ikarian Capital held 370,084 shares of Cogent Biosciences worth $14.3M as of Q2 2026.
  • Cogent Biosciences was a new Ikarian Capital position in Q2 2026.
  • Cogent Biosciences made up 1.54% of Ikarian Capital's portfolio in Q2 2026, its #17 holding.
  • Ikarian Capital first reported a position in Cogent Biosciences in Q4 2020 and has held it in 13 quarters since.
  • 324 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.